US 12,109,241 B2
Methods of manufacture of immunocompatible chorionic membrane products
Samson Tom, Baltimore, MD (US); Alla Danilkovitch, Columbia, MD (US); Dana Yoo, Falls Church, VA (US); Timothy Jansen, Baltimore, MD (US); Jin-Qiang Kuang, Woodstock, MD (US); and Jennifer Michelle Marconi, Glen Burnie, MD (US)
Assigned to OSIRIS THERAPEUTICS, INC., Columbia, MD (US)
Filed by OSIRIS THERAPEUTICS, INC., Columbia, MD (US)
Filed on Jan. 6, 2023, as Appl. No. 18/094,148.
Application 18/094,148 is a continuation of application No. 16/271,038, filed on Feb. 8, 2019, granted, now 11,638,725.
Application 16/271,038 is a continuation of application No. 14/069,894, filed on Nov. 1, 2013, granted, now 10,258,650, issued on Apr. 16, 2019.
Application 14/069,894 is a continuation of application No. 13/030,539, filed on Feb. 18, 2011, abandoned.
Claims priority of provisional application 61/369,562, filed on Jul. 30, 2010.
Claims priority of provisional application 61/338,489, filed on Feb. 18, 2010.
Claims priority of provisional application 61/338,464, filed on Feb. 18, 2010.
Prior Publication US 2023/0381241 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A01N 1/02 (2006.01); A61K 35/50 (2015.01); A61K 38/18 (2006.01); A61K 38/39 (2006.01); A61K 38/57 (2006.01); C12N 5/073 (2010.01)
CPC A61K 35/28 (2013.01) [A01N 1/0221 (2013.01); A61K 35/50 (2013.01); A61K 38/1825 (2013.01); A61K 38/1841 (2013.01); A61K 38/39 (2013.01); A61K 38/57 (2013.01); C12N 5/0605 (2013.01); C12N 2500/02 (2013.01); C12N 2501/115 (2013.01); C12N 2502/025 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method of treating a skin and/or dermal tissue injury of a subject, the method comprising administering to the skin and/or dermal tissue injury of the subject a cryopreserved portion of a placenta,
wherein the cryopreserved placental portion comprises at least 70% viable therapeutic cells native to the placental portion,
wherein the cryopreserved placental portion is substantially depleted of immunogenic cells comprising trophoblasts, functional CD14+ macrophages, or both trophoblasts and functional CD14+ macrophages, and
wherein the cryopreserved placental portion comprises a chorionic membrane of the placenta or the cryopreserved placental portion has a thickness of about 40 μm to about 400 μm.